Literature DB >> 29800369

Hepatitis D Viremia Among Injection Drug Users in San Francisco.

Parag Mahale1, Peter V Aka1,2, Xiaohua Chen3,4, Ping Liu3, Benjamin J Fram5, Alan S Wang1, Scott Simenel5, Fan-Chen Tseng1, Sabrina Chen6, Brian R Edlin7,8, Jeffrey S Glenn3,5, Thomas R O'Brien1.   

Abstract

People who inject drugs (PWID) are commonly exposed to hepatitis B virus (HBV) and hepatitis D virus (HDV). We evaluated the prevalence of HDV viremia among hepatitis B surface antigen (HBsAg)-positive PWID (n = 73) using a new quantitative microarray antibody capture (Q-MAC) assay, HDV western blot, and HDV RNA. HDV Q-MAC performed well in this cohort: anti-HDV, 100% sensitivity and specificity; HDV viremia, 61.5% sensitivity and 100% specificity. Hepatitis D viremia was present in 35.6% of HBsAg-positive participants and was more common in those with resolved compared to chronic hepatitis C (5.1% vs 0.6%; adjusted odds ratio, 9.80; P < .0001).

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29800369      PMCID： PMC5972608          DOI： 10.1093/infdis/jiy157

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  15 in total

1.  Experience with human immunodeficiency virus infection in patients with hepatitis B virus and hepatitis delta virus infections in Los Angeles, 1977-1985.

Authors:  K M De Cock; J C Niland; H P Lu; A Rahimian; V Edwards; K Shriver; S Govindarajan; A G Redeker
Journal:  Am J Epidemiol       Date:  1988-06       Impact factor: 4.897

2.  A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma.

Authors:  Jianguang Ji; Kristina Sundquist; Jan Sundquist
Journal:  J Natl Cancer Inst       Date:  2012-03-14       Impact factor: 13.506

3.  Delta hepatitis: Toward improved diagnostics.

Authors:  Saleem Kamili; Jan Drobeniuc; Tonya Mixson-Hayden; Maja Kodani
Journal:  Hepatology       Date:  2017-10-30       Impact factor: 17.425

4.  Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users.

Authors:  Lauren M Kucirka; Homayoon Farzadegan; Jordan J Feld; Shruti H Mehta; Mark Winters; Jeffrey S Glenn; Gregory D Kirk; Dorry L Segev; Kenrad E Nelson; Morgan Marks; Theo Heller; Elizabeth T Golub
Journal:  J Infect Dis       Date:  2010-09-15       Impact factor: 5.226

Review 5.  Epidemiology of viral hepatitis and HIV co-infection.

Authors:  Miriam J Alter
Journal:  J Hepatol       Date:  2005-11-21       Impact factor: 25.083

Review 6.  Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead.

Authors:  Heiner Wedemeyer; Michael P Manns
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

7.  Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B.

Authors:  G Fattovich; S Boscaro; F Noventa; E Pornaro; D Stenico; A Alberti; A Ruol; G Realdi
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

8.  Hepatitis B markers in United States drug addicts with special emphasis on the delta hepatitis virus.

Authors:  A Ponzetto; L B Seeff; Z Buskell-Bales; K G Ishak; J H Hoofnagle; H J Zimmerman; R H Purcell; J L Gerin
Journal:  Hepatology       Date:  1984 Nov-Dec       Impact factor: 17.425

9.  Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000.

Authors:  Fan-Chen Tseng; Thomas R O'Brien; Mingdong Zhang; Alex H Kral; Betty A Ortiz-Conde; Jennifer Lorvick; Michael P Busch; Brian R Edlin
Journal:  Hepatology       Date:  2007-09       Impact factor: 17.425

Review 10.  Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System.

Authors:  Susan J Bersoff-Matcha; Kelly Cao; Mihaela Jason; Adebola Ajao; S Christopher Jones; Tamra Meyer; Allen Brinker
Journal:  Ann Intern Med       Date:  2017-04-25       Impact factor: 25.391
View more
  7 in total

Review 1.  Recent breakthroughs in the treatment of chronic hepatitis Delta.

Authors:  Giuseppina Brancaccio; Laura Gaeta; Alessandro Vitale; Giovanni B Gaeta
Journal:  Infez Med       Date:  2022-06-01

Review 2.  Pathogenesis of and New Therapies for Hepatitis D.

Authors:  Christopher Koh; Theo Heller; Jeffrey S Glenn
Journal:  Gastroenterology       Date:  2018-10-18       Impact factor: 22.682

Review 3.  A review on hepatitis D: From virology to new therapies.

Authors:  Nathalie Mentha; Sophie Clément; Francesco Negro; Dulce Alfaiate
Journal:  J Adv Res       Date:  2019-03-29       Impact factor: 10.479

4.  Prevalence and risk factors of Hepatitis D virus antibody among asymptomatic carriers of Hepatitis B virus: a community survey.

Authors:  Uchenna C Okonkwo; Henry C Okpara; Kenneth Inaku; Tony M Aluka; Evaristus S Chukwudike; Yeonun Ogarekpe; Emin J Emin; Osim Hodo; Akaninyene A Otu
Journal:  Afr Health Sci       Date:  2022-03       Impact factor: 1.108

5.  Hepatitis D virus infection, cirrhosis and hepatocellular carcinoma in The Gambia.

Authors:  Parag Mahale; Peter Aka; Xiaohua Chen; Ruth M Pfeiffer; Ping Liu; Sarah Groover; Maimuna Mendy; Ramou Njie; James J Goedert; Gregory D Kirk; Jeffrey S Glenn; Thomas R O'Brien
Journal:  J Viral Hepat       Date:  2019-02-14       Impact factor: 3.728

Review 6.  Hepatitis delta virus: From infection to new therapeutic strategies.

Authors:  Grazia A Niro; Arianna Ferro; Francesca Cicerchia; Isabella Brascugli; Marilena Durazzo
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

7.  High Prevalence of Chronic Viral Hepatitis and Liver Fibrosis Among Mongols in Southern California.

Authors:  Tse-Ling Fong; Naranbaatar D Dashdorj; Takeshi Saito; Brian T Lee; Mimi Chang; Khishigsuren Nasanbayar; Enkhjargal Tsogtoo; Delgerbat Boldbaatar; Esugen D Dashdorj; Namuun E Clifford; Arghun N Dashdorj; Bo-Ram Bang; Takeshi Chida; Carolina Lim; Masaya Sugiyama; Masashi Mizokami; Naranjargal J Dashdorj; Ping Liu; Jeffrey S Glenn
Journal:  Dig Dis Sci       Date:  2020-08-08       Impact factor: 3.487
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.